Nuclio News and MyNuclio combine industry journalism, professional networking and commercial intelligence to serve one of healthcare’s fastest-growing sectors
As billions of dollars flow into radiopharmaceuticals, medical isotopes and precision oncology, a new media company is betting that one of healthcare's fastest-growing industries needs more than another publication—it needs its own commercial ecosystem.
Today, Nuclio announced the
launch of Nuclio News, a
digital business publication covering the global nuclear medicine economy,
alongside MyNuclio, a
professional networking platform designed exclusively for organizations and
professionals across the nuclear medicine industry. Together, the platforms
represent a new approach to vertical media, combining business journalism,
industry networking and commercial intelligence into a single ecosystem built
for a specialized healthcare market.
"For decades, the
nuclear medicine industry has relied on fragmented information sources, trade
shows and personal relationships to stay connected," said Brian
Fitzgerald, founder and CEO of Nuclio. "We saw an opportunity to build the
digital infrastructure the industry has never had; a place where companies can
follow the market, professionals can build meaningful industry connections and
the commercial side of nuclear medicine becomes more transparent."
Unlike traditional
healthcare publications that broadly cover life sciences or medical technology,
Nuclio News focuses exclusively on the business of nuclear medicine. Its
editorial coverage spans radiopharmaceutical development, isotope production,
manufacturing, molecular imaging, theranostics, hospital systems, nuclear
pharmacies, artificial intelligence, investment, mergers and acquisitions,
clinical development and the companies shaping the industry's future.
At the same time, MyNuclio
extends beyond publishing by providing professionals and organizations with a
dedicated platform to build profiles, connect with peers, showcase expertise,
claim company pages, post career opportunities and strengthen commercial
relationships across the global nuclear medicine community.
The launch reflects a
broader shift occurring throughout business media, where specialized digital
platforms are increasingly combining content, community and proprietary data
rather than relying solely on traditional advertising models.
"Every major industry
eventually develops digital infrastructure that helps people discover companies,
build relationships and make better business decisions," Fitzgerald said.
"Financial markets have Bloomberg. Venture capital has PitchBook. Sales
teams rely on ZoomInfo. Nuclear medicine has experienced extraordinary
scientific innovation over the past decade, but its commercial infrastructure
has largely remained disconnected. That's the problem we're setting out to
solve."
Nuclio's long-term vision
extends beyond publishing. As organizations and professionals establish
verified profiles and engage with industry content, the company plans to build
a comprehensive commercial graph of the nuclear medicine economy—mapping
companies, products, facilities, partnerships and market relationships to
support future intelligence, recruiting and business development services.
Industry growth has
accelerated dramatically in recent years as radiopharmaceuticals move into
mainstream oncology, driving significant investment in isotope production,
manufacturing capacity, imaging technologies and targeted therapies. Yet much
of the industry's commercial information remains fragmented across disconnected
databases, company websites, conferences and personal networks.
Nuclio believes that
creating a unified digital platform for the sector can help improve market visibility,
facilitate commercial connections and provide deeper insight into one of
healthcare's fastest-evolving markets.
Nuclio News and MyNuclio are
now live and available globally.